ArticleJournal of inflammation (London, England)2026
Diagnostic and prognostic value of LINC00278 in patients with severe pneumonia and its regulatory role.
Article in Journal of inflammation (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the diagnostic and prognostic value and regulatory role of LINC00278 in severe pneumonia.
methodsA total of 312 volunteers were enrolled with a follow-up period of 90 days. Blood and bronchoalveolar lavage fluid samples from participants were stored at −80 °C. ROC curves, KM curves, and multivariate Cox regression analyses assessed LINC00278‘s diagnostic and prognostic utility. RT-qPCR examined gene expression; CCK-8 assays evaluated cell proliferation. ELISA measured inflammatory cytokine expression, while commercially available kits quantified oxidative stress levels. DLR and RIP validated gene-target relationships.
resultsLINC00278 was upregulated in both blood and bronchoalveolar lavage fluid samples from patients with severe pneumonia. Elevated LINC00278 expression predicted poorer patient outcomes. LPS treatment promoted LINC00278 expression in pulmonary epithelial cells, slowed cell proliferation, and increased inflammatory and oxidative stress levels. miR-149-5p was downregulated in critically ill patients and identified as a target gene of LINC00278. The miR inhibitor reversed the cellular functions and inflammatory levels modulated by si-LINC00278. Forty-nine genes were identified as potential downstream targets of the LINC00278/miR-149-5p pathway.
conclusionsLINC00278 impairs pulmonary epithelial cell proliferation by suppressing miR-149-5p, elevating cellular inflammation and oxidative stress levels, thereby contributing to poor prognosis in critically ill pneumonia patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.